CHI3L1 and neoplasm: Finally, prospective randomized trials are necessary to validate the role of YKL-40/c-Met in predicting tumor resistance; if so, the efficacy of neoadjuvant CRT in these patients would benefit of therapy sensitizers, i.e. targeted c-met inhibitors, to improve responsiveness.